PATENT CLAIM ANALYSIS

Application Number: 16079059
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to methods of treating, preventing or managing intestinal fibrosis by inhibiting SMAD7. The invention is also directed to methods of monitoring effectiveness of treatment or management of intestinal fibrosis using a SMAD7 antisense oligonucleotide, as well as methods of regulating SMAD7 antisense oligonucleotide treatment, based on analysis of Transforming Growth Factor-β (TGF-β) levels, α-Smooth Muscle Actin (a-SMA) levels, and/or phosphorylated Mothers Against Decapentaplegic Homolog 3 (p-SMAD3) levels.

Claim (Index 47):
The method of  claim 26  or  28 , wherein, if TGF-\u03b2 levels are above normal levels, the subsequent dose is at least about 10 mg/day, at least about 20 mg/day, at least about 30 mg/day, at least about 40 mg/day, at least about 50 mg/day, at least about 60 mg/day, at least about 70 mg/day, at least about 80 mg/day, at least about 90 mg/day, at least about 100 mg/day, at least about 110 mg/day, at least about 120 mg/day, at least about 130 mg/day, at least about 140 mg/day, at least about 150 mg/day, or at least about 160 mg/day greater than the initial dose.

Metadata:
- Claim Count in Document: 51.0
- Percentile: 96.0
- Lexical Diversity: 1.55556
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15063077', '16046389', '12854558', '14144029', '12264058']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.775547302244633
- 35 USC 102 Novelty (BERT): 0.5411186713197553
- Combined Prediction Score: 0.7521044391521453
- Mean Citation Score: 335.939554
- Max Citation Score: 336.40283
- Similarity Product: 134.4003737401527

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test